STM30006

STM30006 is a potent, small molecule inhibitor of **Methyltransferase Like 3 (METTL3)**, the catalytic subunit of the m6A RNA methyltransferase complex. Developed by **Storm Therapeutics**, STM30006 is a second-generation analog of the tool compound STM2457, designed with improved potency and oral bioavailability. The drug functions by inhibiting the deposition of N6-methyladenosine (m6A) modifications on mRNA transcripts, thereby disrupting the stability and translation of key oncogenic drivers. In the context of **T-cell acute lymphoblastic leukemia (T-ALL)**, STM30006 has been shown to modulate the expression of **MYC** and genes involved in the cholesterol biosynthesis pathway (such as HMGCS1), leading to reduced cell proliferation and increased apoptosis. It is primarily utilized in preclinical research to evaluate the therapeutic potential of targeting the epitranscriptome in hematological malignancies and other cancers.